R. Fleischmann

SAT0575 Safety and efficacy of lutikizumab (ABT-981), an anti–interleukin-1 alpha/beta dual variable domain (DVD) immunoglobulin, in subjects with knee osteoarthritis: results from the randomised, double-blind, placebo-controlled, parallel-group phase 2 trial

Lu Wang, J. Pelletier, J. Martel-Pelletier, 2018, Saturday, 16 JUNE 2018.

A novel Wnt pathway inhibitor, SM04690, for the treatment of moderate to severe osteoarthritis of the knee: results of a 24-week, randomized, controlled, phase 1 study.

M. Hochberg, N. Lane, J. Hood, 2017, Osteoarthritis and cartilage.

SAT0117 Sarilumab, a Subcutaneously-Administered, Fully-Human Monoclonal Antibody Inhibitor of The IL-6 Receptor: Relationship Between Eular Responses and Change from Baseline of Selected Clinical Parameters

M. Genovese, S. Fiore, C. Fan, 2013 .

Safety and efficacy of ocrelizumab in combination with methotrexate in MTX-naive subjects with rheumatoid arthritis: the phase III FILM trial

C. Zerbini, J. Gómez-Reino, R. Fleischmann, 2012, Annals of the rheumatic diseases.

AB0258 Impact of controlling disease activity on regaining normal physical function, and achieving no or limited pain in patients with rheumatoid arthritis treated with baricitinib

R. Alten, F. Leonardis, A. Quebe, 2018, Rheumatoid arthritis – prognosis, predictors and outcome.

Safety and efficacy of elsubrutinib or upadacitinib alone or in combination (ABBV-599) in patients with rheumatoid arthritis and inadequate response or intolerance to biological therapies: a multicentre, double-blind, randomised, controlled, phase 2 trial.

A. Singhal, Gregorio Cortes-Maisonet, E. Drescher, 2022, The Lancet. Rheumatology.